Shilpa Medicare fell 1.25% to Rs 424.30, extending losses for third day.
The stock has declined 1.6% in three sessions from its recent closing high of Rs 431 on 10 February 2021.
In the past six months, the stock has declined by 31.99% while the benchmark Sensex has added 37.61% during the same period.
In a BSE filing made during market hours today, Shilpa Medicare announced the launch of Sunitinib capsules, under the brand name SUNISHIL in India. The Sunitinib capsules has been launched in three strengths of 12.5 mg, 25 mg and 50 mg
Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. The drug is indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Welldifferentiated Pancreatic Neuroendocrine Tumors with Disease Progression in adults.
The problem is tomorrow s variants : Renowned Bay Area epidemiologist predicts prolonged pandemic
FacebookTwitterEmail 3
1of3Larry Brilliant speaks onstage at the HBO Documentary Open Your Eyes Special Screening At The Rubin Museum at Rubin Museum of Art on July 13, 2016 in New York City.Paul Zimmerman / Getty Images 2016Show MoreShow Less
2of3Larry Brilliant in India the 1970s working with the World Health Organization s efforts to eradicate Smallpox. courtesy of Seva Foundation .Seva FoundationShow MoreShow Less
3of3Epidemiologist Larry Brilliant and his wife Girija Brilliant on the Golden Gate Bridge.Courtesy Larry BrilliantShow MoreShow Less
It will take years, not months, to gain the upper hand in the coronavirus pandemic and it will require thinking well beyond our borders, says Dr. Larry Brilliant.
Global KRAS Inhibitors Drug Market Sales Size Opportunity Clinical Development To Surpass USD 1 Billion By 2025
NEW DELHI, Feb. 15, 2021 /PRNewswire/ Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025 Report Highlights:
KRAS Inhibitors Market Opportunity: > USD 1 Billion by 2025
Initially US To Dominate KRAS Inhibitors Market: >90% Market Share
Number of KRAS Inhibitors In Trials: > 20 Drugs
Highest Phase of Clinical Development: Phase-III Study
Solid Tumors Targeted Drugs Dominating The Clinical Trials
Global KRAS Inhibitors Market Trends & Dynamics
Global KRAS Inhibitors Market Future Opportunity Outlook
Download Report: https://www.kuickresearch.com/report-global-us-kras-inhibitors-market-g12c-amg-510-sotorasib approval-market-kras-clinical-trials-kras-sales-market-size-kras nsclc-lung-cancer
Table of Content 1.1 Overview
2. Role of KRAS Inhibitors in Cancer
Read more about Shilpa Medicare launches Sunitinib Capsules under brand name SINISHIL on Business Standard. Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor withantitumor and antiangiogenic activities.
Date Time
CCTV released in St Kilda robbery investigation
Detectives from the Port Phillip Criminal Investigation Unit have released CCTV footage of a woman in relation to a robbery in St Kilda last month.
Investigators have been told an unknown woman forced an 84-year-old man into a public toilet before stealing his cash and Medicare card about 3pm, 19 January.
Police have released CCTV of a woman inside a nearby licensed premises a short time after the incident.
Detectives believe this woman could assist with their investigation.
She is perceived to be of Aboriginal appearance, approximately 30-40 years old with a solid build, wearing a blue floral dress and white head scarf.